Xtalks — The Life Science Community™, Online webinar
2026-09-08
Poor drug solubility continues to be one of the most significant challenges in small molecule drug development, impacting bioavailability, formulation design, clinical performance, timelines and overall development risk. With an estimated 80-90% of molecules currently in development exhibiting poor solubility characteristics, sponsors are increasingly seeking integrated strategies that can accelerate decision-making while reducing the risk of costly reformulation and scale-up challenges. In this webinar, expert speakers will explore how a connected development strategy can help sponsors successfully navigate solubility challenges from early development through clinical supply. The session will examine how understanding a molecule's physicochemical properties and biopharmaceutic profile, coupled with a flexible clinical development plan and objectives, can guide the selection and optimization of the most appropriate formulation approach and enabling technology. Attendees will gain insight into the key considerations for selecting between approaches such as hot melt extrusion (HME), spray dried dispersions (SDD), lipid-based formulations and particle size reduction technologies, while also learning how early formulation decisions can influence future scale-up, manufacturing robustness, regulatory strategy and commercial readiness. The webinar will cover amorphous solid dispersion development considerations, including stable ASD development through HME and spray drying pathways. It will also examine how scalable development strategies can support formulation continuity from first-in-human studies through later-stage clinical development. Real-world examples will illustrate how integrated development models can help accelerate formulation optimization, generate clinically relevant data earlier and support informed decisions throughout the product lifecycle. The session will provide practical guidance for evaluating formulation options, planning clinical supply and developing a fit-for-purpose strategy that balances scientific, clinical and commercial considerations. Register for this webinar to learn how drug solubility strategies can reduce formulation and scale-up risk throughout small molecule development.
|